Commentary · 2 Jan 2026
Short communicationPublished 21 Jun 2020
Bone Metastases in Metastatic Renal Cell Carcinoma: Now We Know That Cabozantinib Targets Bone Microenvironment
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The multiple tyrosine kinases inhibitor cabozantinib has shown improvements in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) in comparison to everolimus in patients with metastatic renal cell carcinoma (mRCC) within the METEOR trial, a phase III clinical trial , randomized, open-label trial [1,2], resulting in its approval in mRCC patients previously treated with antiangiogenic agents.
Keywords
Subjects
SurgeryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Transplant Reports : Open Access.
Commentary · 2 Jan 2026
Pathology’s Vital Role in Solid Organ Transplantation Outcomes
Short communication · 1 Jan 2026
Transplant Registries: Data, Analytics, and Future Innovations
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalTransplant Reports : Open Access
- SubjectSurgery
- BylineArticles whose byline prints “Giuseppe Procopio”